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Thyroid function and metabolic syndrome
in the population-based LifeLines cohort
study
Bruce H. R. Wolffenbuttel1*, Hanneke J. C. M. Wouters1, Sandra N. Slagter1, Robert P. van Waateringe1,
Anneke C. Muller Kobold2, Jana V. van Vliet-Ostaptchouk1, Thera P. Links1 and Melanie M. van der Klauw1
Abstract
Background: The metabolic syndrome (MetS) is a combination of unfavourable health factors which includes abdominal
obesity, dyslipidaemia, elevated blood pressure and impaired fasting glucose. Earlier studies have reported a relationship
between thyroid function and some MetS components or suggested that serum free thyroxine (FT4) or free
triiodothyronine (FT3) levels within the normal range were independently associated with insulin resistance.
We assessed how thyroid function relates to MetS prevalence in a large population-based study.
Methods: Data of 26,719 people of western European descent, aged 18–80 years from the Dutch LifeLines
Cohort study, all with normal thyroid stimulating hormone (TSH), FT4 and FT3 levels (electrochemiluminescent
immunoassay, Roche Modular E170 Analyzer), were available. MetS was defined with the revised National
Cholesterol Education Programs Adults Treatment Panel III (NCEP ATP III) criteria. We calculated prevalence of
all MetS components according to TSH, FT4 and FT3 quartiles.
Results: At similar TSH levels and age (mean 45 yrs), men had significantly higher levels of FT4, FT3, blood
pressure (BP), heart rate, total and LDL-cholesterol, triglycerides (TG), and creatinine, but lower HDL-cholesterol
compared to women (all p < 0.001). In total, 11.8% of women and 20.7% of men had MetS. In men, lower
FT4 levels were associated with higher prevalence of MetS and all MetS components. In women, lower FT4
quartile was only associated with a higher prevalence of elevated TG, waist circumference, and MetS.
However, when corrected for confounding factors like age, BMI, current smoking and alcohol consumption, a
significant relationship was found between FT3 and three MetS components in men, and all five components
in women. Moreover, the highest quartiles of FT3 and the FT3FT4 ratio predicted a 49% and 67% higher
prevalence of MetS in men, and a 62 and 80% higher prevalence in women.
Conclusions: When corrected for possible confounding factors, higher plasma levels of FT3 are associated
with several components of the MetS. Only in men, lower FT4 is related to MetS. In the highest FT3 and
FT3FT4 quartiles, there is a 50–80% increased risk of having MetS compared to the lowest quartile. Further
studies are needed to assess the possible causality of this relationship.
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Background
The metabolic syndrome (MetS) is a clustering of med-
ical conditions that reflects overnutrition, sedentary life-
styles, and resultant adiposity. Metabolic abnormalities
such as abdominal obesity, hyperglycaemia, hypertension
and dyslipidaemia often are present together, suggesting
that they are not independent of one another and that
they may share underlying causes and mechanisms [1].
Having MetS places a subject at a substantially increased
risk to develop serious diseases like type 2 diabetes
(T2D) and cardiovascular disease (CVD) [2].
In an earlier paper we described results from the
population-based PREVEND study, and reported that
low normal free thyroxine (FT4) levels were significantly
related to a higher prevalence of all five MetS compo-
nents in a group of almost 2300 people from the general
population [3]. From this, we concluded that subjects
with thyroid function in the low normal range already
are at increased cardiovascular risk.
In recent years, there have been confusing results on
the relationship between thyroid hormone levels within
the normal range and cardiovascular risk factors and
MetS. Several papers have described a relationship be-
tween thyroid hormone parameters and components of
MetS [3–7]. However, some authors have reported an
association between thyroid stimulating hormone (TSH)
levels and metabolic risk factors, whereas others have
observed that high normal free triiodothyronine (FT3)
levels, and the FT3FT4-ratio were related to MetS. One
of the largest study until now [4] evaluated 44,196 indi-
viduals (of whom 25,147 men), and reported that FT4 in
men was significantly associated with blood pressure
(BP), HDL-cholesterol (HDL-C), fasting blood glucose
(FBG), and triglycerides (TG), and in women was associ-
ated with BP, HDL-C, FBG, waist circumference (WC).
The authors however did not see an association with
MetS, when adjusted for age. They did not adjust for
smoking or alcohol, two important factors which influ-
ence the prevalence of MetS components, like low HDL-
C, elevated triglycerides (TG), and -in women- increased
WC [8]. Another study from Korea evaluated data from
13,496 middle-aged individuals, and found a relationship
between higher T3 and T3/T4 and an unfavourable
metabolic profile [6]. And a very recent paper reported
in over 132,000 subjects that higher FT3/FT4 ratio was
associated with increased risk of metabolic syndrome pa-
rameters and insulin resistance, adjusted for age, body
mass index, smoking status and menopausal status (in
women) [7].
For the current study, we used data of 26,719 partici-
pants from the population-based LifeLines Cohort Study
to address the discrepancies in the literature. We aimed
to investigate the relationship between thyroid hormone
parameters and components of the MetS in this large
sample of euthyroid subjects in the general population.
As differences in MetS prevalence and thyroid hormone
parameters have been demonstrated between men and




For this cross-sectional study, we obtained data from sub-
jects participating in the LifeLines Cohort Study. LifeLines
is a multi-disciplinary prospective population-based cohort
study examining in a unique three-generation design the
health and health-related behaviours of persons living in
the North of The Netherlands. It started in 2007, and em-
ploys a broad range of investigative procedures in assessing
the biomedical, socio-demographic, behavioural, physical
and psychological factors which contribute to the health
and disease of the general population, with a special focus
on multi-morbidity and complex genetics. The method-
ology has been described previously [9, 10]. All participants
provided written informed consent before entering the
study. The study protocol was approved by the medical
ethical review committee of the University Medical Center
Groningen. For the present study, we included subjects
with an age between 18 and 80 years, who were of Western
European descent, in whom thyroid hormone parameters
were measured, and found to be within the normal range.
We excluded participants who were treated because of a
thyroid disorder, or who were current users of drugs
known to influence thyroid hormone parameters, like lith-
ium, amiodarone, and corticosteroids. Also, participants
with a CRP level > 10 mg/L were excluded, because inflam-
mation may disturb the activity of the deiodinase enzymes
and alter thyroid hormone levels.
Clinical examination
Subjects completed a self-administered questionnaire on
medical history, past and current diseases, use of medi-
cation and health behaviour at home. Medication use
was verified by a certified research assistant, and scored
by ATC code. The number of different medications used
by a participant was considered as a proxy for multimor-
bidity [11]. Participants were defined as never smoker,
current smoker or former smoker. Alcohol intake was
calculated as the average number of units of alcohol
based on the response to specific questions regarding in-
take frequency. Individuals who reported that they had
not consumed alcohol during the previous month were
considered non-drinkers.
BP and anthropometric measurements were obtained
using a standardized protocol [9, 10]. BP was measured
every minute during a period of 10 min with an auto-
mated DINAMAP Monitor (GE Healthcare, Freiburg,
Germany). The average of the final three readings was
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recorded for systolic and diastolic BP. Height, weight,
and waist and hip circumference were measured with
the participant in light clothing and without shoes [8].
Biochemical measurements
Blood samples were collected between 8 and 10 a.m.
after an overnight fast, directly into tubes containing
heparin, and centrifuged. Total cholesterol (TC) and
HDL-cholesterol (HDL-C) were measured with an en-
zymatic colorimetric method, triglycerides (TG) with
UV colorometry, and LDL-cholesterol (LDL-C) using an
enzymatic method (Roche Modular P chemistry analyser,
Roche, Basel, Switzerland). HbA1c was measured with
a turbidimetric inhibition immunoassay (Cobas Inte-
gra 800 CTS analyser, Roche Diagnostics Nederland
BV, Almere, the Netherlands). Fasting blood glucose
was measured using a hexokinase method. Levels of
thyroid stimulating hormone (TSH), as well as free
thyroxine (FT4) and free triiodothyronine (FT3) were
assayed by electrochemiluminescent immunoassay
(Roche Modular E170, Roche, Switzerland) [12]. Nor-
mal values for TSH are 0.4–4.5 mU/l, FT4 are 11–
20 pmol/L, for FT3 4.4–6.7 pmol/l. The general
Dutch population is iodine sufficient. Tests to meas-
ure anti-thyroid peroxidase antibody levels were not
performed.
Calculations, definitions and statistical analysis
Body mass index (BMI) was calculated as weight (kg)/
height (m2), and categorized as normal weight (<25 kg/m2),
overweight (25–30 kg/m2) and obesity (≥ 30 kg/m2). Diag-
nosis of type 2 diabetes was based either on self-report
(known diabetes), or on the finding of a fasting blood glu-
cose ≥7.0 mmol/l at LifeLines’ screening (newly-diagnosed
diabetes) [13]. Diagnosis of MetS was established if a sub-
ject satisfied at least three out of five criteria according to
the modified guidelines of the National Cholesterol Educa-
tion Programs Adults Treatment Panel III (NCEP ATPIII
criteria) [1, 8]. Relevant parameters were calculated accord-
ing to FT4 and FT3 quartiles. As it is known that women
and men differ regarding cardiovascular parameters, as well
as MetS and thyroid hormone parameters, all calculations
were made for both sexes separately.
Analyses were carried out with PASW Statistics (Ver-
sion 24, IBM, Armonk, NY, USA). Data are presented as
mean ± SD, or median and interquartile range when not
normally distributed. Means were compared between
groups with analysis of variance. In case of non-normal
distribution, medians were compared with the nonpara-
metric Kruskal-Wallis test. Chi-square test was used to
analyse categorical variables. Both smoking and alcohol
alter various components of the MetS [8]. Multiple lin-
ear regression models were therefore created to assess
the associations of thyroid hormone parameters with the
components of the MetS, with and without correction
for factors known to influence either thyroid hormone
parameters and MetS components: age, BMI, current
smoking, and alcohol consumption. We subsequently
used logistic regression analysis to estimate the odds ra-
tios (ORs) and 95% confidence intervals (CI) for quar-
tiles of thyroid hormone parameters to predict the
presence of MetS, again adjusted for age, BMI, as well as
smoking and alcohol consumption. To allow adjustment
for multiple comparisons, a P-value <0.001 was consid-
ered statistically significant.
Results
The characteristics of the participants are given for men
and women separately in Table 1. At similar TSH levels
and age (mean 45 yrs), men had significantly higher
levels of FT4, FT3, BP, heart rate, total and LDL-C, TG,
and creatinine, but lower HDL-C compared to women
(all p < 0.001). In total, 11.8% of women and 20.7% of
men had MetS.
In men, lower FT4 levels were associated with lower
levels of FT3 and higher TSH levels, higher levels of
BMI, WC, waist-to-hip ratio, BP, FBG, total and LDL-C
and TG levels, but lower HDL-C. In the lowest FT4
quartile, there were also fewer current smokers. In con-
trast, lower FT3 quartiles were only associated with
lower FT4, higher TSH, and higher age, and also with
higher levels of TC, HDL-C and LDL-C, and with a
lower percentage of current smokers. As a consequence,
lower FT4 levels were associated with higher prevalence
of all MetS components. The lowest FT4 quartile (Add-
itional file 1: Table S1) was associated with the highest
prevalence of elevated BP (60%), elevated FBG (22.7%),
WC (33.4%) and TG (30.2%), low HDL-cholesterol
(26.5%), and MetS (27.7%). In contrast, higher FT3 levels
were associated only with low HDL-C.
In women, the lowest FT4 quartile was associated with
lower FT3 and higher TSH, higher BMI and waist cir-
cumference, but not with age, or with differences in
blood pressure or cholesterol levels, while triglyceride
levels were slightly higher. As a consequence, low FT4
levels (Additional file 2: Table 2) were only associated
with elevated TG (11.2%), WC (47.4%), and MetS
(13.8%). In contrast, higher FT3 levels were associated
only with low HDL-C, and with a higher percentage of
participants with ≥3 MetS components.
It became apparent that age, BMI and current smoking
were confounders in all analyses: higher age was associ-
ated with lower FT3, and the lower FT4 and FT3 quar-
tiles contained fewer current smokers. Also, age, BMI,
smoking and alcohol consumption are known to influ-
ence several MetS components. Therefore, we per-
formed four models within linear regression analyses, in
which model 4 corrects for all these confounders. The
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results of these analyses are depicted in Tables 2 and 3,
and show some differences between men and women. In
men, only the association between FT4 and TG
remained significant after correcting for all confounders,
while FT3 correlated with 3 of 5 MetS components (BP,
HDL-C, WC). In women, FT3 was associated with all
MetS components after correction for the confounders.
In both men and women, the FT3FT4-ratio was associ-
ated 4 of the 5 components of MetS, but not with FBG.
Finally, Tables 4 and 5 depicts the results of the logis-
tic regression analyses, in which we have correlated the
thyroid parameters (divided in quartiles again) with the
presence of MetS. In both men and women, higher
levels of FT3 and the FT3FT4-ratio, adjusted for age,
BMI, current smoking and alcohol consumption, were
associated with a higher risk MetS, while FT4 was asso-
ciated with higher risk of MetS in men only. Both for
men and women, we observed a 1.67–1.80 higher OR
for the highest FT3FT4-ratio quartile compared to the
lowest quartile to predict the presence of MetS.
Discussion
In this large population-based study in subjects with thy-
roid hormone levels in the normal range, we have shown
that higher levels of FT3 and the FT3FT4 ratio and
lower levels of FT4 (in men only) are associated with
components of MetS, when corrected for important con-
founders like age, BMI, current smoking and alcohol
consumption. A significant relationship was found for
FT3 and three MetS components in men, and all five
components in women. Moreover, the highest quartiles
of FT3 and the FT3FT4 ratio predicted a 49% and 67%
higher prevalence of MetS in men, and a 62 and 80%
higher prevalence in women.
From our uncorrected analyses, FT4 levels appeared
the most strongly related to MetS. However, it has been
known that both age and BMI can influence thyroid hor-
mone parameters and MetS. In the current study, we ob-
served a gradual decrease of plasma FT3 levels with
increasing age, while TSH and FT4 levels did not change
significantly. Furthermore, it is known that FT4 levels
are lower and TSH levels are higher in obese individuals
compared to those with normal weight. This was the
reason we included both parameters as confounders in
our linear regression models. In addition, both smoking
and alcohol consumption have a profound effect on
some MetS components. Smoking lowers HDL-C levels,
and is associated with increased WC, as we have
Table 1 Baseline characteristics of the participants
Men Women P-value
N = 11.819 N = 14.900
Age (years) 46 ± 13 45 ± 13 <0.001
BMI (kg/m2) 26.5 ± 3.5 25.7 ± 4.4 <0.001
Waist (cm) 96 ± 10 87 ± 12 <0.001
Waist-hip ratio 0.97 ± 0.07 0.87 ± 0.07 <0.001
FT3 5.46 ± 0.53 5.10 ± 0.52 <0.001
FT4 16.1 ± 1.9 15.5 ± 1.8 <0.001
TSH 2.11 ± 0.85 2.20 ± 0.90 <0.001
Normal weight/overweight
/obesity (n,%) 35.1/51.0/13.9 37.2/47.9/14.9 NS
Current/never smokers (%) 17.5/42.3 33.1/43.4 <0.001/NS
Systolic BP (mmHg) 131 ± 14 122 ± 15 <0.001
Diastolic BP (mmHg) 77 ± 9 72 ± 9 <0.001
Heart rate (b/min) 70 ± 11 72 ± 10 <0.001
Creatinine (mcmol/l) 83 ± 12 68 ± 9 <0.001
Fasting glucose (mmol/l) 5.2 ± 0.8 4.9 ± 0.7 <0.001
HbA1c (%) 5.6 ± 0.4 5.6 ± 0.4 <0.001
Total cholesterol (mmol/l) 5.16 ± 1.00 5.01 ± 0.98 <0.001
HDL-cholesterol (mmol/l) 1.29 ± 0.31 1.60 ± 0.39 <0.001
LDL-cholesterol (mmol/l) 3.38 ± 0.89 3.06 ± 0.88 <0.001
Triglycerides (mmol/l) 1.15 (0.84–1.66) 0.86 (0.65–1.18) <0.001
% with metabolic syndrome 20.7 11.8 <0.001
% with type 2 diabetes 2.9 1.7 <0.001
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demonstrated earlier within the LifeLines population [8].
Alcohol consumption may increase HDL-C levels, but
also levels of BP [8, 14, 15]. As our initial data analyses
revealed that there were fewer smokers and users of al-
cohol in the lowest FT4 and FT3 quartiles, both in men
and in women, we have corrected in our regression
models for these factors as well. And only with these im-
portant adjustments, we were able to demonstrate that
FT3 levels and the FT3FT4 ratio were significantly asso-
ciated with MetS components, and having MetS.
Several papers have described the relationship between
thyroid hormone parameters and components of MetS. In
2007, our group has demonstrated in the population-based
PREVEND study the association between levels of FT4
(within the normal reference range) and plasma lipids;
these findings were in accordance with the earlier observed
association between (sub)clinical hypothyroidism and
hyperlipidaemia [3]. Low normal FT4 levels proved to be
significantly associated with MetS (four of five components)
and increased insulin resistance. From our data, we con-
cluded that this suggested an increased risk of cardiovascu-
lar events in subjects with low normal thyroid function [3].
Several additional papers, as summarized in Table 6, have
been published the last decade which have assessed the re-
lationship between thyroid hormone levels and cardiovas-
cular risk factors, including the MetS. These studies have
been performed in populations with different ethnic back-
ground. As can be seen in Table 6, there are significant dif-
ferences between these studies, not only related to study
setting and population, but also related to the results. One
of the striking differences is that several papers have not
separated between women and men, as it is known (which
Table 2 Associations of thyroid function with components of the metabolic syndrome in men
FT4 FT3 TSH FT3FT4
Model β P β P β P β P
SBP 1 −0.048 <0.001 0.008 0.385 0.009 0.330 0.049 <0.001
2 −0.013 0.147 0.096 <0.001 0.003 0.705 0.074 <0.001
3 −0.016 0.084 0.093 <0.001 0.003 0.741 0.075 <0.001
4 0.015 0.098 0.081 <0.001 0.005 0.576 0.040 <0.001
DBP 1 −0.048 <0.001 −0.047 <0.001 −0.017 0.066 0.009 0.304
2 −0.005 0.584 0.054 <0.001 −0.024 0.007 0.039 <0.001
3 −0.006 0.486 0.052 <0.001 −0.027 0.002 0.039 <0.001
4 0.020 0.023 0.041 <0.001 −0.026 0.003 0.009 0.312
HDL-C 1 0.044 <0.001 −0.097 <0.001 −0.016 0.086 −0.112 <0.001
2 0.060 <0.001 −0.072 <0.001 −0.018 0.048 −0.103 <0.001
3 0.065 <0.001 −0.063 <0.001 −0.032 <0.001 −0.100 <0.001
4 0.023 0.008 −0.045 <0.001 −0.035 <0.001 −0.051 <0.001
TG 1 −0.084 <0.001 0.011 0.246 0.057 <0.001 0.083 <0.001
2 −0.074 <0.001 0.040 <0.001 0.076 <0.001 0.092 <0.001
3 −0.081 <0.001 0.027 0.005 0.068 <0.001 0.090 <0.001
4 −0.040 <0.001 0.010 0.286 0.070 <0.001 0.041 <0.001
FBG 1 −0.074 <0.001 −0.040 <0.001 −0.003 0.710 0.038 <0.001
2 −0.042 <0.001 0.037 <0.001 −0.009 0.333 0.062 <0.001
3 −0.043 <0.001 0.036 <0.001 −0.008 0.353 0.062 <0.001
4 −0.014 0.112 0.024 0.010 −0.007 0.456 0.028 0.001
Waist 1 −0.143 <0.001 −0.018 0.051 −0.015 0.106 0.119 <0.001
2 −0.105 <0.001 0.079 <0.001 −0.021 0.016 0.148 <0.001
3 −0.106 <0.001 0.079 <0.001 −0.021 0.017 0.148 <0.001
4 −0.002 0.657 0.036 <0.001 −0.015 0.001 0.0125 <0.001
Values of β are standardized regression coefficients
Regression for triglycerides was performed after logarithmic transformation. Significant associations are shown in bold
Model 1: crude
Model 2: after adjustment for age
Model 3: after adjustment for age, current smoking, alcohol consumption
Model 4: after adjustment for age, BMI, current smoking, alcohol consumption
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is also apparent from the current paper) that the prevalence
of the individual MetS components differs considerably be-
tween women and men [16–19]. For instance, we have re-
cently demonstrated that increased waist circumference is a
common features of MetS among women while men have
often an elevated blood pressure [20]. Moreover, FT4 and
FT3 levels differ between men and women as well. There-
fore, simply adjusting for sex may obscure possible differ-
ences between sexes. In addition, no study has reported
data on smoking and alcohol consumption, or corrected for
these important confounders. Interestingly, our data indi-
cate a dysbalance of smoking and alcohol consumption in
the different FT4 and FT3 quartiles, which causes a warn-
ing regarding the proper interpretation of earlier studies.
With the exception of recent studies by Kim et al. [4], Park
et al. [5] and by Kim et al. [6, 21], earlier studies have incor-
porated a limited number of participants.
There are a number of possible explanations for the
relationship between FT3 and the different MetS com-
ponents, c.q. insulin resistance. One may be that a small
increase of T3 may directly influence insulin sensitivity.
Recent data have supported this with the notion that
overproduction of thyroid hormones may have a nega-
tive effect on peripheral insulin action [22]. Indeed, it
has been shown that in obese individuals, who more fre-
quently are insulin-resistant, FT4 levels are lower, and
TSH and FT3 levels are higher. This has been postulated
to be the consequence of an excess of nutrition, espe-
cially when consuming a diet high in fat. Obesity may
directly influence tissue type 2 deiodinase activity -which
converts T4 into T3- in order to compensate for this. It
has also been argued that in the brain T3 may have a
stimulatory effect on food intake behaviour, which can
be considered a compensation for the increase of
Table 3 Associations of thyroid function with components of the metabolic syndrome in women
FT4 FT3 TSH FT3FT4
Model β P β P β P β P
SBP 1 0.034 <0.001 0.040 <0.001 0.033 <0.001 0.006 0.455
2 0.027 <0.001 0.131 <0.001 0.025 0.001 0.081 <0.001
3 0.028 <0.001 0.137 <0.001 0.023 0.002 0.083 <0.001
4 0.054 <0.001 0.130 <0.001 0.018 0.015 0.054 <0.001
DBP 1 −0.003 0.754 0.015 0.06 0.007 0.426 0.017 0.044
2 −0.007 0.400 0.064 <0.001 0.002 0.823 0.058 <0.001
3 −0.006 0.461 0.068 <0.001 0.000 0.962 0.059 <0.001
4 0.014 0.078 0.063 <0.001 −0.004 0.658 0.037 <0.001
HDL-C 1 0.016 0.046 −0.112 <0.001 0.020 0.016 −0.106 <0.001
2 0.013 0.107 −0.079 <0.001 0.016 0.047 −0.078 <0.001
3 0.023 0.005 −0.062 <0.001 0.001 0.877 −0.071 <0.001
4 −0.016 0.034 −0.052 <0.001 0.009 0.240 −0.027 <0.001
TG 1 −0.068 <0.001 0.046 <0.001 0.078 <0.001 0.105 <0.001
2 −0.073 <0.001 0.101 <0.001 0.073 <0.001 0.154 <0.001
3 −0.083 <0.001 0.086 <0.001 0.087 <0.001 0.150 <0.001
4 −0.051 <0.001 0.078 <0.001 0.080 <0.001 0.113 <0.001
FBG 1 0.000 0.964 −0.011 0.161 0.036 <0.001 −0.003 0.731
2 −0.007 0.405 0.059 <0.001 0.029 <0.001 0.057 <0.001
3 −0.007 0.405 0.059 <0.001 0.029 <0.001 0.056 <0.001
4 0.025 0.001 0.051 <0.001 0.023 0.002 0.020 0.011
Waist 1 −0.091 <0.001 −0.011 0.175 0.018 0.032 0.081 <0.001
2 −0.096 <0.001 0.048 <0.001 0.012 0.137 0.134 <0.001
3 −0.097 <0.001 0.047 <0.001 0.014 0.084 0.133 <0.001
4 −0.004 0.380 0.024 <0.001 −0.005 0.284 0.024 <0.001
Values of β are standardized regression coefficients
Regression for triglycerides was performed after logarithmic transformation. Significant associations are shown in bold
Model 1: crude
Model 2: after adjustment for age
Model 3: after adjustment for age, current smoking, alcohol consumption
Model 4: after adjustment for age, BMI, current smoking, alcohol consumption
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Table 4 Risk of having metabolic syndrome according to quartiles of thyroid hormone parameters, in men
Quartile MetS/Total, n (%) model 1 model 2 model 3 model 4
TSH 1 578/2923 (19.8) 1 1 1 1
2 595/2975 (20.0) 1.014 (0.893–1.153) 1.015 (0.892–1.155) 1.030 (0.904–1.174) 1.000 (0.861–1.161)
3 618 (2946 (21.0) 1.077 (0.948–1.223) 1.072 (0.943–1.219) 1.116 (0.980–1.271) 1.101 (0.949–1.276)
4 650/2975 (21.8) 1.134 (1.000–1.286) 1.110 (0.977–1.261) 1.155 (1.015–1.314) 1.214 (1.047–1.407)
FT4 1 796/2877 (27.7) 1 1 1 1
2 635/3000 (21.2) 0.702 (0.623–0.791) # 0.717 (0.635–0.809) # 0.704 (0.623–0.796) # 0.816 (0.709–0.939) #
3 532/3014 (17.7) 0.560 (0.495–0.635) # 0.596 (0.525–0.675) # 0.579 (0.509–0.657) # 0.733 (0.634–0.848) #
4 478/2928 (16.3) 0.510 (0.449–0.579) # 0.567 (0.498–0.646) # 0.545 (0.478–0.622) # 0.722 (0.621–0.839) #
FT3 1 516/2655 (19.4) 1 1 1 1
2 652/3300 (19.8) 1.021 (0.897–1.161) 1.192 (1.045–1.360) 1.172 (1.026–1.339) # 1.174 (1.010–1.366)
3 695/3185 (21.8) 1.157 (1.018–1.315) 1.487 (1.302–1.699) # 1.458 (1.275–1.668) # 1.360 (1.167–1.586) #
4 578/2679 (21.6) 1.140 (0.998–1.303) 1.652 (1.434–1.904) # 1.577 (1.366–1.821) # 1.491 (1.266–1.756) #
FT3FT4 1 457/2945 (15.5) 1 1 1 1
2 528/2958 (17.8) 1.183 (1.031–1.357) 1.241 (1.080–1.426) 1.220 (1.060–1.405) # 1.234 (1.054–1.445)
3 667/2960 (22.5) 1.584 (1.388–1.807) # 1.753 (1.533–2.005) # 1.731 (1.512–1.983) # 1.537 (1.318–1.791) #
4 789/2956 (26.7) 1.982 (1.743–2.255) # 2.263 (1.984–2.582) # 2.267 (1.984–2.590) # 1.674 (1.438–1.948) #
Model 1: crude; model 2: adjusted for age; model 3: adjusted for age, current smoking and alcohol consumption
model 4: adjusted for age, BMI, current smoking and alcohol consumption
OR and 95% CI for metabolic syndrome were calculated using logistic regression models
Significant associations (P < 0.001) are shown in bold
Table 5 Risk of having metabolic syndrome according to quartiles of thyroid hormone parameters, in women
Quartile MetS/Total, n (%) model 1 model 2 model 3 model 4
TSH 1 388/3726 (10.4) 1 1 1 1
2 428/3710 (11.5) 1.122 (0.970–1.298) 1.149 (0.989–1.334) 1.192 (1.025–1.386) 1.162 (0.984–1.372)
3 451/3729 (12.1) 1.184 (1.025–1.367) 1.165 (1.005–1.351) 1.219 (1.049–1.417) 1.046 (0.885–1.236)
4 493/3735 (13.2) 1.308 (1.136–1.507) # 1.212 (1.053–1.061) 1.288 (1.110–1.494) 1.167 (0.990–1.375)
FT4 1 523/3784 (13.8) 1 1 1 1
2 417/3707 (11.2) 0.790 (0.689–0.907) 0.761 (0.660–0.876) # 0.757 (0.656–0.874) # 0.854 (0.728–1.002)
3 423/3624 (11.7) 0.824 (0.718–0.945) 0.762 (0.661–0.877) # 0.758 (0.657–0.874) # 0.900 (0.767–1.057)
4 397/3785 (10.5) 0.731 (0.636–0.840) # 0.651 (0.564–0.752) # 0.620 (0.535–0.717) # 0.819 (0.696–0.964)
FT3 1 317/3104 (10.2) 1 1 1 1
2 482/4361 (11.1) 1.095 (0.943–1.272) 1.179 (1.011–1.375) 1.154 (0.988–1.348) 1.095 (0.923–1.299)
3 521/3897 (13.4) 1.357 (1.170–1.574) # 1.644 (1.410–1.916) # 1.558 (1.334–1.819) # 1.515 (1.276–1.798) #
4 439/3538 (12.4) 1.245 (1.068–1.452) 1.819 (1.550–2.134) # 1.707 (1.451–2.008) # 1.622 (1.354–1.942) #
FT3FT4 1 374/3724 (10.0) 1 1 1 1
2 392/3718 (10.5) 1.056 (0.909–1.226) 1.227 (1.051–1.432) 1.217 (1.041–1.423) 1.241 (1.045–1.473)
3 438/3726 (11.8) 1.193 (1.031–1.381) 1.557 (1.337–1.813) # 1.539 (1.319–1.795) # 1.423 (1.201–1.687) #
4 556/3732 (14.9) 1.568 (1.364–1.803) # 2.372 (2.045–2.751) # 2.329 (2.004–2.705) # 1.798 (1.522–2.125) #
Model 1: crude; model 2: adjusted for age; model 3: adjusted for age, current smoking and alcohol consumption
model 4: adjusted for age, BMI, current smoking and alcohol consumption
OR and 95% CI for metabolic syndrome were calculated using logistic regression models
Significant associations (P < 0.001) are shown in bold
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metabolic rate which is induced by the thyroid hormone
itself [23]. This author suggested that T3 may stimulate
specific neurons that influence appetite-increasing
neuropeptides. However, in our data we did observe
lower FT4 and higher TSH levels with increasing BMI,
but no significant changes of FT3. However, changes in
Table 6 Studies evaluating the relationship between thyroid hormone levels and components of the metabolic syndrome
Author,
year







28–75 yrs No Age, sex, HOMA-IR FT4 negative association with TC, LDL-C,
TG and waist, positive association with
HDL-C, FT3 negative association with TC,
LDL-C, TG
[3]
Park, 2009 949 Postmeno-
pausal women
Women only Age, BMI, HOMA-IR,
FT4, exercise (3 levels),
alcohol (3 levels)





25–70 yrs Yes Age Men: FT4 associated with BP, HDL-C, FBG,
TG, and with WC in those over 50; Women:
associated with BP, HDL-C, FBG, WC; no




3033 18–70 yrs No Age, sex TSH associated with TC, TG, WC; FT4





>18 yrs No Age TSH positively associated with BMI, TG,




>18 yrs No Age, sex, BMI, smoking
(y/n), alcohol (y/n),
exercise (y/n)
TSH and FT4 associated with WC, FBG,
HDL-C, FT4 also with DBP; higher TSH
predicted MetS at follow-up
[5]
Tarcin, 2012 211, 24 M Obesity,
18–73 yrs
No Age FT3/FT4 negatively associated with FBG,
TG, BP,




2119 70–79 yrs No Age, sex, race, BMI,
smoking, HOMA-IR
TSH associated with MetS prevalence, in
entire cohort with broad range of TSH
levels, and in euthyroid range
[34]
Oh, 2013 2760 18–39 Women only Age, BMI, HOMA-IR TSH between 2.5 and 4.5 associated with




Middle-aged No Age, sex, height,
current smoking
FT3 and FT3/FT4 ratio positively associated
with BMI, WC, TG, BP, FBG, negatively with
HDL-C; FT4 negatively associated






≥20 yrs No Age, sex, smoking,
BMI, HOMA-IR
FT4 associated with HDL-C, LDL-C, TG, WC,








Yes None Higher FT3/FT4 ratio in boys with MetS; no




3533 M 20–65 yrs Men only Age, alcohol
consumption, smoking
(never, former, current)
Higher TSH & lowest FT4 quintiles






No Age, sex, % body fat,
smoking, HOMA-IR
Higher quartiles of T3 and T3/T4 ratio
associated with MetS; only measured






No Age, sex, smoking Highest T3 quartile associated with highest
6-year MetS incidence; only measured total




940 30–60 yrs No Age, sex, BMI, WHR,
family history of diabetes
Higher FT3 associated with decreased
insulin sensitivity (insulin clamp), predicted




>18 yrs Yes Age, BMI, smoking
status, menopausal
status (in women)
FT3FT4 ratio associated with increased risk
of MetS parameters and insulin resistance
[7]
BMI body mass index, BP blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, HDL-C high-density-lipoprotein-cholesterol, HOMA-IR
homeostasis-model assessment - insulin resistance, LDL-C low-density-lipoprotein-cholesterol, M males, MetS metabolic syndrome, SCH subclinical hypothyroidism,
TC total cholesterol, TG triglycerides, WC waist circumference, WHR waist-to-hip ratio, yrs. years, y/n yes/no
Wolffenbuttel et al. BMC Endocrine Disorders  (2017) 17:65 Page 8 of 11
brain T3 production may not be mirrored by similar
changes in plasma FT3. Another explanation may be
that MetS or insulin resistance itself may lead to a rela-
tive higher intracellular production of T3 as a way to
compensate -on a local tissue level- for the disturbances
in the metabolic state [24, 25]. The increase in local T3
production may be intended to limit nutrient overload
by inducing tissue thermogenesis and simulating meta-
bolic activity [25, 26]. It has also been postulated that
3,5-diiodo-l-thyronine (T2) has marked effects on energy
metabolism in order to protect skeletal muscle against
excessive intramyocellular lipid storage [27], that may
occur in MetS. A positive energy balance both as a con-
sequence of caloric excess and due to insufficient phys-
ical activity may contribute to this. In contrast, caloric
restriction and prolonged fasting have been associated
with lower type 2 deiodinase activity, which will reduce
the conversion of T4 to T3 and lower plasma (F)T3
levels, and an increase in the conversion to reverse T3.
In addition, the slightly lower (F)T4 levels observed in
obesity themselves may upregulate tissue type 2 deiodi-
nase activity, thereby leading to a relative increase of T3.
Other factors which may influence tissue deiodinase ac-
tivity and thereby resulting T3 levels are changes in cir-
cadian rhythm. Indeed, it has been shown that
disturbances in sleep pattern may play a role in the de-
velopment of obesity and diabetes [28, 29].
Our study has several strengths, but also some weak-
nesses. It comprises a large dataset of participants from
the general population with available thyroid hormone
parameters. Also, all subjects have been uniformly char-
acterized, with well-standardized BP measurements and
blood drawing in the fasting state, thereby minimizing
the effect of possible circadian changes in thyroid hor-
mone parameters. The large number of participants
allowed to assess all relationships for men and women
separately, which is of importance considering the sig-
nificant differences between sexes for a large number of
baseline characteristics (Table 1). As mentioned, this is
one of the few studies in which confounding factors like
smoking and alcohol have been taken into account. Cur-
rently, we lack information regarding menopausal status
of the female participants, which may influence the pos-
sible difference between sexes. Also, data on physical
activity could not be taken into account, and it is known
that this factor may directly influence some MetS com-
ponents, and is an important factor in maintaining an
optimal energy balance. Tests to measure anti-thyroid
peroxidase antibody levels were not available. Due to the
cross-sectional design, we can not evaluate the effects of
thyroid hormone parameters on future development of
MetS. This also relates to the fact that the LifeLines
study did not systematically collect medication use dur-
ing follow-up investigations.
Conclusions
In conclusion, plasma levels of both FT4 and FT3 are asso-
ciated with several components of the MetS, after correc-
tion for possible important confounding factors. In the
highest FT3 and FT3FT4 quartiles there is a 50–80% in-
creased risk of having MetS compared to the lowest quar-
tile. Further studies are needed to assess the possible
causality of this relationship.
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